Trabedersen clinical trials
Also written OT-101 and AP 12009.
How each study uses Trabedersen is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Trabedersen studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2005 | 1 |
| 2008 | 1 |
| 2021 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 3
Isarna Therapeutics GmbH (3) · Oncotelic Inc. (3) · University of Nebraska (1) · Ocumension (Hong Kong) Limited (1) · University of Washington (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test Trabedersen, phase 3 first.
- Mar 2027Study of OT-101 in Treating MyopiaPhase 3 · Ocumension (Hong Kong) Limited
Studies
Open first, then newest update. How each study uses Trabedersen is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic CancerRecruitingPhase 2/3Oncotelic Inc.NCT06079346Written as OT-101
- OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint InhibitionNot yet recruitingPhase 2Oncotelic Inc.NCT05425576Written as OT-101
- Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1Active, not recruitingPhase 1/2University of NebraskaNCT06579196Written as Trabedersen
- OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung CancerWithdrawnPhase 2University of WashingtonNCT05935774Written as Trabedersen (OT-101)
- Study of OT-101 in Treating MyopiaActive, not recruitingPhase 3Ocumension (Hong Kong) LimitedNCT04770610Written as OT-101 Ophthalmic Solution
- A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 SubjectsStatus unknownPhase 2Oncotelic Inc.NCT04801017Written as OT-101
- Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2CompletedPhase 1Isarna Therapeutics GmbHNCT00844064Written as AP 12009
- Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary GlioblastomaTerminatedPhase 3Isarna Therapeutics GmbHNCT00761280Written as trabedersen
- Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade GliomaCompletedPhase 2Isarna Therapeutics GmbHNCT00431561Written as AP 12009 10 µM
Codes
What other systems call Trabedersen · ClinicalTrials.gg INT005209
- MeSH (NLM) C525712TrabedersenConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 98OYR854NYTRABEDERSENConfirmed FDA, NLM, Wikidata
- Wikidata Q28816121trabedersenConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C80066TrabedersenConfirmed FDA, Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C525712 | Trabedersen | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 98OYR854NY | TRABEDERSEN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q28816121 | trabedersen | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C80066 | Trabedersen | Confirmed FDA, Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.